Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. I...
Enregistré dans:
Auteurs principaux: | Schneider RE, Barakat AY, Pippen JE, Osborne CR |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b517bf99f4fc4d218a09d68e37c7adb0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
par: Bauer M, et autres
Publié: (2012) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
par: Mo QG, et autres
Publié: (2016) -
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations
par: Neil M. Iyengar, et autres
Publié: (2021) -
Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
par: Xue-Ying Zhu, et autres
Publié: (2021) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
par: Butani D, et autres
Publié: (2021)